Please login to the form below

Not currently logged in
Email:
Password:

MDD

This page shows the latest MDD news and features for those working in and with pharma, biotech and healthcare.

Janssen submits esketamine in Europe for treatment resistant depression

Janssen submits esketamine in Europe for treatment resistant depression

Esketamine is a glutamate receptor modulator, for treatment-resistant depression (TRD) in adults with Major Depressive Disorder (MDD). ... Having gained two FDA breakthrough therapy designations (one in TRD, the other in MDD with imminent risk for suicide

Latest news

  • Sage surges after depression drug gets rapid path to approval Sage surges after depression drug gets rapid path to approval

    SAGE-217 is being tested in post-partum depression (PPD) that affects mother after childbirth as well as major depressive disorder (MDD), for which Sage reported positive phase 2 results last ... results due later this year are positive - and a single,

  • Alkermes slumps as FDA turns down depression drug Alkermes slumps as FDA turns down depression drug

    Alkermes was hoping that the massive unmet need in patients with MDD would help sway the FDA. ... Despite the large number of approved agents, the majority of MDD patients treated with standard antidepressants do not achieve adequate relief.

  • Lundbeck partners with 23andMe on first-of-its-kind study Lundbeck partners with 23andMe on first-of-its-kind study

    The US project will involve 25, 000 patients and combine data from genetics, cognitive tests and online surveys to explore how genetics is related to major depressive disorder (MDD), bipolar depression ... Anders Gersel Pedersen, executive VP, research

  • Allergan pushes on with Botox for depression Allergan pushes on with Botox for depression

    MDD), but still thinks it is worth testing the drug in phase III. ... The specialty pharma group took the decision to test Botox in depression after external research groups showed evidence of efficacy in MDD in two separate early-stage trials.

  • Takeda pilots Apple Watch depression app Takeda pilots Apple Watch depression app

    Partners with Cognition Kit on patient monitoring wearable.  . Takeda is testing the use of an Apple Watch app for patients with major depressive disorder (MDD). ... Working with UK firm Cambridge Cognition the company is piloting the app to monitor and

More from news
Approximately 2 fully matching, plus 21 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics